Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Caprion Partners CellCarta Technology With ImClone

Jan. 11, 2006

By Jennifer Boggs

Caprion Partners CellCarta Technology With ImClone

Jan. 11, 2006

By Jennifer Boggs

Xytis Series B: $25M For Trials In Schizophrenia, Brain Injury

Jan. 10, 2006

By Jennifer Boggs

Xytis Series B: $25M For Trials In Schizophrenia, Brain Injury

Jan. 10, 2006

By Jennifer Boggs

KAI's PKC Program Nabs $340M Deal With Sankyo

Jan. 9, 2006

By Jennifer Boggs

KAI Pharmaceuticals Inc. signed a potential $340 million deal expected to be announced today with Daiichi Sankyo Co. Ltd. for the global development and commercialization of KAI-9803. (BioWorld Today)

KAI's PKC Program Nabs $340M Deal With Sankyo

Jan. 9, 2006

By Jennifer Boggs

KAI Pharmaceuticals Inc. signed a potential $340 million deal expected to be announced today with Daiichi Sankyo Co. Ltd. for the global development and commercialization of KAI-9803. (BioWorld Today)

Innovive Adding Dual Inhibitor To Oncology Pipeline For CML

Jan. 6, 2006

By Jennifer Boggs

Diversa Cuts Staff, Focuses Efforts On Late-Stage Work

Jan. 6, 2006

By Jennifer Boggs

Diversa Cuts Staff, Focuses Efforts On Late-Stage Work

Jan. 6, 2006

By Jennifer Boggs

Innovive Adding Dual Inhibitor To Oncology Pipeline For CML

Jan. 6, 2006

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for August 12, 2025.
Bayer secures KRAS G12D inhibitor with $1.3B Kumquat deal
BioWorld
With a packed pipeline of drug candidates targeting multiple markers of cancer, Bayer AG signed on for a new project, this time going after the KRAS pathway with...
NME Digest: Q2 2025
BioWorld
A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
KDCA readies mRNA vaccines, tech for COVID-19, future outbreaks
BioWorld
Korea Disease Control and Prevention Agency (KDCA) secured 5.3 million doses of COVID-19 vaccines made by Pfizer Inc./Biontech SE and Moderna Inc., officially...